PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 1997 March; 71(3): 2083–2091.
PMCID: PMC191297

Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation.

Abstract

Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vivo through the introduction of amino acid substitutions into either the polyprotein cleavage junctions or the PR coding sequence. Single amino acid substitutions (V(P2)S and P(P4)G), which are predicted from in vitro peptide substrate cleavage data to decrease the rate of release of PR from the Gag polyprotein, were placed in the NC portion of the NC-PR junction. These substitutions do not affect the efficiency of release of virus-like particles from COS cells even though recovered particles contain significant amounts of uncleaved Pr76gag in addition to mature viral proteins. Single amino acid substitutions (A(P3)F and S(P1)Y), which increase the rate of PR release from Gag, also do not affect budding of virus-like particles from cells. Substitution of the inefficiently cleaved MA-p2 junction sequence in Gag by eight amino acids from the rapidly cleaved NC-PR sequence resulted in a significant increase in cleavage at the new MA-p2 junction, but again without an effect on budding. However, decreased budding was observed when the A(P3)F or S(P1)Y substitution was included in the NC-PR junction sequence between the MA and p2 proteins. A budding defect was also caused by substitution into Gag of a PR subunit containing three amino acid substitutions (R105P, G106V, and S107N) in the substrate binding pocket that increase the catalytic activity of PR. The defect appears to be the result of premature proteolytic processing that could be rescued by inactivating PR through substitution of a serine for the catalytic aspartic acid residue. This budding defect was also rescued by single amino acid substitutions in the NC-PR cleavage site which decrease the rate of release of PR from Gag. A similar budding defect was caused by replacing the Gag PR with two PR subunits covalently linked by four glycine residues. In contrast to the defect caused by the triply substituted PR, the budding defect observed with the linked PR dimer could not be rescued by NC-PR cleavage site mutations, suggesting that PR dimerization is a limiting step in the maturation process. Overall, these results are consistent with a model in which viral protein maturation occurs after PR subunits are released from the Gag polyprotein.

Full Text

The Full Text of this article is available as a PDF (1.8M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aiyar A, Xiang Y, Leis J. Site-directed mutagenesis using overlap extension PCR. Methods Mol Biol. 1996;57:177–191. [PubMed]
  • Bennett RP, Nelle TD, Wills JW. Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol. 1993 Nov;67(11):6487–6498. [PMC free article] [PubMed]
  • Bizub D, Weber IT, Cameron CE, Leis JP, Skalka AM. A range of catalytic efficiencies with avian retroviral protease subunits genetically linked to form single polypeptide chains. J Biol Chem. 1991 Mar 15;266(8):4951–4958. [PubMed]
  • Bryant M, Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A. 1990 Jan;87(2):523–527. [PubMed]
  • Burstein H, Bizub D, Skalka AM. Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol. 1991 Nov;65(11):6165–6172. [PMC free article] [PubMed]
  • Burstein H, Bizub D, Kotler M, Schatz G, Vogt VM, Skalka AM. Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol. 1992 Mar;66(3):1781–1785. [PMC free article] [PubMed]
  • Cameron CE, Grinde B, Jacques P, Jentoft J, Leis J, Wlodawer A, Weber IT. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J Biol Chem. 1993 Jun 5;268(16):11711–11720. [PubMed]
  • Cameron CE, Grinde B, Jentoft J, Leis J, Weber IT, Copeland TD, Wlodawer A. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. J Biol Chem. 1992 Nov 25;267(33):23735–23741. [PubMed]
  • Cameron CE, Ridky TW, Shulenin S, Leis J, Weber IT, Copeland T, Wlodawer A, Burstein H, Bizub-Bender D, Skalka AM. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem. 1994 Apr 15;269(15):11170–11177. [PubMed]
  • Campbell S, Vogt VM. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol. 1995 Oct;69(10):6487–6497. [PMC free article] [PubMed]
  • Crawford S, Goff SP. A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol. 1985 Mar;53(3):899–907. [PMC free article] [PubMed]
  • Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses. 1992 Feb;8(2):153–164. [PubMed]
  • Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996 Jun;70(6):3763–3769. [PMC free article] [PubMed]
  • Erikson E, Brugge JS, Erikson RL. Phosphorylated and nonphosphorylated forms of avian sarcoma virus polypeptide p19. Virology. 1977 Jul 1;80(1):177–185. [PubMed]
  • Grinde B, Cameron CE, Leis J, Weber IT, Wlodawer A, Burstein H, Bizub D, Skalka AM. Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem. 1992 May 15;267(14):9481–9490. [PubMed]
  • Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. [PubMed]
  • Katz RA, Skalka AM. The retroviral enzymes. Annu Rev Biochem. 1994;63:133–173. [PubMed]
  • Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686–4690. [PubMed]
  • Kräusslich HG. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3213–3217. [PubMed]
  • Leis J, Phillips N, Fu X, Tuazon PT, Traugh JA. Phosphorylation of avian retrovirus matrix protein by Ca2+/phospholipid-dependent protein kinase. Eur J Biochem. 1989 Feb 1;179(2):415–422. [PubMed]
  • Pepinsky RB, Papayannopoulos IA, Chow EP, Krishna NK, Craven RC, Vogt VM. Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses. J Virol. 1995 Oct;69(10):6430–6438. [PMC free article] [PubMed]
  • Ridky T, Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem. 1995 Dec 15;270(50):29621–29623. [PubMed]
  • Ridky TW, Bizub-Bender D, Cameron CE, Weber IT, Wlodawer A, Copeland T, Skalka AM, Leis J. Programming the Rous sarcoma virus protease to cleave new substrate sequences. J Biol Chem. 1996 May 3;271(18):10538–10544. [PubMed]
  • Séllos-Moura M, Vogt VM. Proteolytic activity of purified avian sarcoma and leukemia virus NC-PR protein expressed in Escherichia coli. Virology. 1996 Jul 15;221(2):335–345. [PubMed]
  • Stewart L, Schatz G, Vogt VM. Properties of avian retrovirus particles defective in viral protease. J Virol. 1990 Oct;64(10):5076–5092. [PMC free article] [PubMed]
  • Weber IT. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J Biol Chem. 1990 Jun 25;265(18):10492–10496. [PubMed]
  • Weldon RA, Jr, Wills JW. Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol. 1993 Sep;67(9):5550–5561. [PMC free article] [PubMed]
  • Wills JW, Craven RC, Achacoso JA. Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol. 1989 Oct;63(10):4331–4343. [PMC free article] [PubMed]
  • Wills JW, Craven RC. Form, function, and use of retroviral gag proteins. AIDS. 1991 Jun;5(6):639–654. [PubMed]
  • Wills JW, Craven RC, Weldon RA, Jr, Nelle TD, Erdie CR. Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol. 1991 Jul;65(7):3804–3812. [PMC free article] [PubMed]
  • Wills JW, Cameron CE, Wilson CB, Xiang Y, Bennett RP, Leis J. An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol. 1994 Oct;68(10):6605–6618. [PMC free article] [PubMed]
  • Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 1993;62:543–585. [PubMed]
  • Xiang Y, Cameron CE, Wills JW, Leis J. Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol. 1996 Aug;70(8):5695–5700. [PMC free article] [PubMed]
  • Zhang ZY, Poorman RA, Maggiora LL, Heinrikson RL, Kézdy FJ. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem. 1991 Aug 25;266(24):15591–15594. [PubMed]
  • Zybarth G, Kräusslich HG, Partin K, Carter C. Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. J Virol. 1994 Jan;68(1):240–250. [PMC free article] [PubMed]
  • Zybarth G, Carter C. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J Virol. 1995 Jun;69(6):3878–3884. [PMC free article] [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)